604 related articles for article (PubMed ID: 26780098)
21. Central corneal thickness and intraocular pressure before the intravitreal administration of ranibizumab and in the early period following the injection.
Biatas-Niedziela D; Olechowski A; Ciszewska J; Switka-Wiectawska I; Kecik D
Klin Oczna; 2016 Aug; 118(1):11-17. PubMed ID: 29715401
[TBL] [Abstract][Full Text] [Related]
22. Effect of prior glaucoma surgery on intraocular pressure immediately after anti-vascular endothelial growth factor injection.
Lam J; Luttrell I; Ding L; Rezaei K; Chao JR; Chee Y; Olmos De Koo LC; Wen JC
Graefes Arch Clin Exp Ophthalmol; 2019 Nov; 257(11):2489-2494. PubMed ID: 31388743
[TBL] [Abstract][Full Text] [Related]
23. Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice.
Maloney MH; Payne SR; Herrin J; Sangaralingham LR; Shah ND; Barkmeier AJ
Ophthalmology; 2021 Mar; 128(3):417-424. PubMed ID: 32781110
[TBL] [Abstract][Full Text] [Related]
24. Effect of prophylactic medication and influence of vitreous reflux in pressure rise after intravitreal injections of anti-VEGF drugs.
Carnota-Méndez P; Méndez-Vázquez C; Otero-Villar J; Saavedra-Pazos JA
Eur J Ophthalmol; 2014; 24(5):771-7. PubMed ID: 24706353
[TBL] [Abstract][Full Text] [Related]
25. Long-term intraocular pressure changes after intravitreal injection of bevacizumab.
Baek SU; Park IW; Suh W
Cutan Ocul Toxicol; 2016 Dec; 35(4):310-4. PubMed ID: 26820610
[TBL] [Abstract][Full Text] [Related]
26. EFFECT OF SERIAL ANTERIOR CHAMBER PARACENTESIS ON SUSTAINED INTRAOCULAR PRESSURE ELEVATION IN PATIENTS RECEIVING INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
Sisk RA; Rusia D; Zamora BG; Kuley A; Toussaint BW
Retina; 2019 Oct; 39(10):1959-1964. PubMed ID: 30234855
[TBL] [Abstract][Full Text] [Related]
27. Long-term dynamic changes and influencing factors of corneal morphology after multiple intravitreal injections of anti-VEGF drugs.
Qi Y; Li C; Ye S; Zhang Z; Li S; Zhang L
Medicine (Baltimore); 2024 Apr; 103(17):e37937. PubMed ID: 38669379
[TBL] [Abstract][Full Text] [Related]
28. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.
Tseng JJ; Vance SK; Della Torre KE; Mendonca LS; Cooney MJ; Klancnik JM; Sorenson JA; Freund KB
J Glaucoma; 2012; 21(4):241-7. PubMed ID: 21423038
[TBL] [Abstract][Full Text] [Related]
29. Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion.
Pfau M; Fassnacht-Riederle H; Becker MD; Graf N; Michels S
Ophthalmic Res; 2015; 54(3):150-6. PubMed ID: 26413794
[TBL] [Abstract][Full Text] [Related]
30. The effect and safety of intravitreal injection of ranibizumab and bevacizumab on the corneal endothelium in the treatment of diabetic macular edema.
Guzel H; Bakbak B; Koylu MT; Gonul S; Ozturk B; Gedik S
Cutan Ocul Toxicol; 2017 Mar; 36(1):5-8. PubMed ID: 26911396
[TBL] [Abstract][Full Text] [Related]
31. Same-Day Bilateral Intravitreal Anti-Vascular Endothelial Growth Factor Injections: Experience of a Large Canadian Retina Center.
Juncal VR; Francisconi CLM; Altomare F; Chow DR; Giavedoni LR; Muni RH; Berger AR; Wong DT
Ophthalmologica; 2019; 242(1):1-7. PubMed ID: 30928983
[TBL] [Abstract][Full Text] [Related]
32. Long-term effects of multiple intravitreal antivascular endothelial growth factor injections on intraocular pressure.
Kim YJ; Sung KR; Lee KS; Joe SG; Lee JY; Kim JG; Yoon YH
Am J Ophthalmol; 2014 Jun; 157(6):1266-1271.e1. PubMed ID: 24561173
[TBL] [Abstract][Full Text] [Related]
33. Longitudinal Changes in Retinal Nerve Fiber Layer Thickness after Intravitreal Anti-vascular Endothelial Growth Factor Therapy.
Jo YJ; Kim WJ; Shin IH; Kim JY
Korean J Ophthalmol; 2016 Apr; 30(2):114-20. PubMed ID: 27051259
[TBL] [Abstract][Full Text] [Related]
34. Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials.
Bakri SJ; Moshfeghi DM; Francom S; Rundle AC; Reshef DS; Lee PP; Schaeffer C; Rubio RG; Lai P
Ophthalmology; 2014 May; 121(5):1102-8. PubMed ID: 24393349
[TBL] [Abstract][Full Text] [Related]
35. Risk of Intraocular Pressure Increase With Intravitreal Injections of Vascular Endothelial Growth Factor Inhibitors: A Cohort Study.
Spini A; Giometto S; Donnini S; Posarelli M; Dotta F; Ziche M; Tosi GM; Girardi A; Lucenteforte E; Gini R; Etminan M; Virgili G
Am J Ophthalmol; 2023 Apr; 248():45-50. PubMed ID: 36410468
[TBL] [Abstract][Full Text] [Related]
36. Ghost cell glaucoma after intravitreous injection of ranibizumab in proliferative diabetic retinopathy.
Xu J; Zhao M; Li JP; Liu NP
BMC Ophthalmol; 2020 Apr; 20(1):149. PubMed ID: 32295566
[TBL] [Abstract][Full Text] [Related]
37. Long-term effect of anti-vascular endothelial growth factor injections on intraocular pressure.
Nariani A; Williams B; Hariprasad SM
Indian J Ophthalmol; 2016 Sep; 64(9):643-647. PubMed ID: 27853011
[TBL] [Abstract][Full Text] [Related]
38. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.
Zehetner C; Kirchmair R; Huber S; Kralinger MT; Kieselbach GF
Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630
[TBL] [Abstract][Full Text] [Related]
39. Retinal nerve fiber layer thickness in patients receiving chronic anti-vascular endothelial growth factor therapy.
Horsley MB; Mandava N; Maycotte MA; Kahook MY
Am J Ophthalmol; 2010 Oct; 150(4):558-561.e1. PubMed ID: 20643396
[TBL] [Abstract][Full Text] [Related]
40. The 12- and 24-Month Effects of Intravitreal Ranibizumab, Aflibercept, and Bevacizumab on Intraocular Pressure: A Network Meta-Analysis.
Nanji K; Sarohia GS; Kennedy K; Ceyhan T; McKechnie T; Phillips M; Devji T; Thabane L; Kaiser P; Sarraf D; Garg SJ; Sivaprasad S; Wykoff CC; Bakri SJ; Sheidow T; Bhandari M; Chaudhary V
Ophthalmology; 2022 May; 129(5):498-508. PubMed ID: 34871637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]